Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Terminated 5Recruiting 5Completed 5Active not recruiting 5Withdrawn 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Breast Neoplasms 292Carcinoma, Non-Small-Cell Lung 206Prostatic Neoplasms 158Lung Neoplasms 93Stomach Neoplasms 69Neoplasms 69Head and Neck Neoplasms 60Squamous Cell Carcinoma of Head and Neck 56Neoplasm Metastasis 50Esophageal Neoplasms 49Ovarian Neoplasms 39Pancreatic Neoplasms 26Sarcoma 23Carcinoma, Ovarian Epithelial 20Urinary Bladder Neoplasms 19Unspecified Adult Solid Tumor, Protocol Specific 19Breast Neoplasms, Male 17Adenocarcinoma Of Esophagus 17Parkinson Disease 4, Autosomal Dominant Lewy Body 16Esophageal Squamous Cell Carcinoma 16Adenocarcinoma of Lung 16Fallopian Tube Neoplasms 14Carcinoma, Squamous Cell 14Adenocarcinoma 12Melanoma 11Inflammatory Breast Neoplasms 11Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Salivary Gland Neoplasms 8Endometrial Neoplasms 8

Interventions

pembrolizumab 25Gemcitabine 21Nivolumab 17Cisplatin 17atezolizumab 14Carboplatin 11avelumab 9vinflunine 7Ipilimumab 7Paclitaxel 6Docetaxel 5enfortumab vedotin 4cabazitaxel 4Pemetrexed 4Mitomycin 4cabozantinib 3Taxes 3Rogaratinib 3Magnetic Resonance Spectroscopy 3Injections 3Albumin-Bound Paclitaxel 3tremelimumab 2sacituzumab govitecan 2pemigatinib 2niraparib 2lenvatinib 2bempegaldesleukin 2apatorsen 2XRP6258 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Carcinoma, Transitional Cell × Docetaxel × Clear all
NCT03575013 2025-12-03

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

University of Iowa

Phase 1 Completed
21 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT02426125 2023-08-21

RANGE

Eli Lilly and Company

Phase 3 Completed
530 enrolled 22 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

NCT01780545 2022-07-11

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Hoosier Cancer Research Network

Phase 2 Completed
200 enrolled 11 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00880334 2018-09-18

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

Dana-Farber Cancer Institute

Phase 2 Completed
149 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚔